A Phase 2 interventional study of MLS-101 (Part I) and Placebo (Part I) in Hypertension, Renal, sponsored by Mineralys Therapeutics Inc.. Completed at 44 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-05.
Sponsored by Mineralys Therapeutics Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A randomized, double-blind, placebo-controlled, dose-ranging, Phase II study to evaluate the safety, efficacy, and tolerability of MLS-101 in Subjects With Uncontrolled Hypertension
Mineralys Therapeutics Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Strong and CYP3A4 inducers
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo tablet(s) by mouth once or twice daily.
Other: Placebo (Part I)
MLS-101 tablet(s) by mouth once or twice daily.
Drug: MLS-101 (Part I)
MLS-101 tablet(s) by mouth once or twice daily.
Drug: MLS-101 (Part I)
MLS-101 tablet(s) by mouth once or twice daily.
Drug: MLS-101 (Part I)
Placebo tablet(s) by mouth once daily.
Other: Placebo (Part II)
MLS-101 tablet(s) by mouth once daily.
Drug: MLS-101 (Part II)
MLS-101 tablet(s) by mouth once or twice daily.
Placebo tablet(s) by mouth once or twice daily.
Placebo tablet(s) by mouth once daily.
MLS-101 tablet(s) by mouth once daily.
Change From Baseline in Office-measured Systolic Blood Pressure (SBP) at Study Week 8 Compared to Placebo
The primary outcome was defined as the change in office-measured (mean of last 2 of 5 unattended measurements using an automated oscillometric sphygmomanometer device after approximately 5 minutes of rest in the seated position) SBP from baseline to the end of Study Week 8. The primary efficacy analysis was performed using a mixed model repeated measures (MMRM) approach with defined fixed effects per the statistical analysis plan. A least-square estimate of the mean difference between each dose group and the placebo group is provided for Week 8.
Time frame: 8 Weeks
Change in 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean Systolic Blood Pressure (SBP) and Mean Diastolic Blood Pressure (DBP) From Baseline to End of Treatment (EoT)
The ABPM SBP was measured at baseline and EoT. Change in ABPM-derived mean SBP and DBP from baseline to EoT was analyzed using an ANCOVA with a term for treatment group and a baseline mean 24-hour value as a covariate.
Time frame: 8 Weeks
Week 8 Change From Baseline in Office-measured Diastolic Blood Pressure (DBP)
Change in office-measured (average of last 2 of 5 unattended measurements using an automated oscillometric sphygmomanometer device after approximately 5 minutes of rest in the seated position) DBP from baseline to the end of study at week 8.
Time frame: 8 weeks
Number of Participants With Blood Pressure ≤ 130/80 mmHg at Week 8
Each participant was assessed as a success if the Week 8 value for SBP was ≤130 mmHg and DBP ≤80 mmHg; subjects not meeting both these thresholds were assessed as a failure. Subjects missing an assessment at Week 8 or who received rescue medications were also considered failures.
Time frame: 8 Weeks
| Milestone | Placebo - Part 1 | Lorundrostat 12.5 mg BID - Part 1 | Lorundrostat 25 mg BID - Part 1 | Lorundrostat 12.5 mg QD - Part 1 | Lorundrostat 50 mg QD - Part 1 | Lorundrostat 100 mg QD - Part 1 | Placebo - Part 2 | Lorundrostat 100 mg QD - Part 2 |
|---|---|---|---|---|---|---|---|---|
| Started | 30 | 22 | 30 | 23 | 28 | 30 | 6 | 31 |
| Completed | 29 | 18 | 28 | 18 | 26 | 27 | 6 | 30 |
| Not completed | 1 | 4 | 2 | 5 | 2 | 3 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 2 | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 |
| Withdrew: Not specified by investigator | 0 | 3 | 0 | 0 | 1 | 0 | 0 | 0 |
The primary outcome was defined as the change in office-measured (mean of last 2 of 5 unattended measurements using an automated oscillometric sphygmomanometer device after approximately 5 minutes of rest in the seated position) SBP from baseline to the end of Study Week 8. The primary efficacy analysis was performed using a mixed model repeated measures (MMRM) approach with defined fixed effects per the statistical analysis plan. A least-square estimate of the mean difference between each dose group and the placebo group is provided for Week 8.
| mmHg | Placebo - Part 1 | Lorundrostat 12.5 mg BID - Part 1 | Lorundrostat 25 mg BID - Part 1 | Lorundrostat 12.5 mg QD - Part 1 | Lorundrostat 50 mg QD - Part 1 | Lorundrostat 100 mg QD - Part 1 | Placebo - Part 2 | Lorundrostat 100 mg QD - Part 2 |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Office-measured Systolic Blood Pressure (SBP) at Study Week 8 Compared to Placebo | -4.10 ± 2.62 | -11.3 ± 3.15 | -11.07 ± 2.65 | -5.63 ± 3.16 | -13.69 ± 2.67 | -11.92 ± 2.77 | — | -11.43 ± 2.41 |
The ABPM SBP was measured at baseline and EoT. Change in ABPM-derived mean SBP and DBP from baseline to EoT was analyzed using an ANCOVA with a term for treatment group and a baseline mean 24-hour value as a covariate.
| mmHg | Placebo - Part 1 | Lorundrostat 12.5 mg BID - Part 1 | Lorundrostat 25 mg BID - Part 1 | Lorundrostat 12.5 mg QD - Part 1 | Lorundrostat 50 mg QD - Part 1 | Lorundrostat 100 mg QD - Part 1 | Placebo - Part 2 | Lorundrostat 100 mg QD - Part 2 |
|---|---|---|---|---|---|---|---|---|
| Mean SBP | -1.01 ± 2.38 | -5.78 ± 3.03 | -9.05 ± 2.38 | -2.51 ± 3.15 | -4.86 ± 2.34 | -6.34 ± 2.5 | — | -1.02 ± 2.64 |
| Mean DBP | -0.90 ± 1.46 | -5.14 ± 1.85 | -6.03 ± 1.45 | -2.34 ± 1.91 | -3.64 ± 1.40 | -6.14 ± 1.51 | — | -0.07 ± 1.69 |
Change in office-measured (average of last 2 of 5 unattended measurements using an automated oscillometric sphygmomanometer device after approximately 5 minutes of rest in the seated position) DBP from baseline to the end of study at week 8.
| mmHg | Placebo - Part 1 | Lorundrostat 12.5 mg BID - Part 1 | Lorundrostat 25 mg BID - Part 1 | Lorundrostat 12.5 mg QD - Part 1 | Lorundrostat 50 mg QD - Part 1 | Lorundrostat 100 mg QD - Part 1 | Placebo - Part 2 | Lorundrostat 100 mg QD - Part 2 |
|---|---|---|---|---|---|---|---|---|
| Week 8 Change From Baseline in Office-measured Diastolic Blood Pressure (DBP) | -1.63 ± 1.66 | -5.47 ± 2.02 | -4.12 ± 1.68 | -3.76 ± 2.02 | -7.09 ± 1.70 | -5.75 ± 1.77 | — | -5.55 ± 1.42 |
Each participant was assessed as a success if the Week 8 value for SBP was ≤130 mmHg and DBP ≤80 mmHg; subjects not meeting both these thresholds were assessed as a failure. Subjects missing an assessment at Week 8 or who received rescue medications were also considered failures.
| Participants | Placebo - Part 1 | Lorundrostat 12.5 mg BID - Part 1 | Lorundrostat 25 mg BID - Part 1 | Lorundrostat 12.5 mg QD - Part 1 | Lorundrostat 50 mg QD - Part 1 | Lorundrostat 100 mg QD - Part 1 | Placebo - Part 2 | Lorundrostat 100 mg QD - Part 2 |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Blood Pressure ≤ 130/80 mmHg at Week 8 | 7 | 7 | 13 | 6 | 12 | 9 | 3 | 17 |
Collected over 12 weeks; two weeks for Run-in Phase treatment-emergent adverse events (TEAEs) reporting and ten weeks for on-treatment (i.e., post-randomization) TEAE reporting.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo - Part 1 | 0/30 (0%) | 0/30 (0%) | 7/30 (23.3%) |
| Lorundrostat 12.5 mg BID - Part 1 | 0/22 (0%) | 0/22 (0%) | 13/22 (59.1%) |
| Lorundrostat 25 mg BID - Part 1 | 0/30 (0%) | 0/30 (0%) | 18/30 (60%) |
| Lorundrostat 12.5 mg QD - Part 1 | 0/23 (0%) | 2/23 (8.7%) | 16/23 (69.6%) |
| Lorundrostat 50 mg QD - Part 1 | 0/28 (0%) | 0/28 (0%) | 10/28 (35.7%) |
| Lorundrostat 100 mg QD - Part 1 | 0/30 (0%) | 0/30 (0%) | 16/30 (53.3%) |
| Placebo - Part 2 | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Lorundrostat 100 mg QD - Part 2 | 0/31 (0%) | 1/31 (3.2%) | 19/31 (61.3%) |
| Run-in | 0/305 (0%) | 0/305 (0%) | 8/305 (2.6%) |
| Event | Placebo - Part 1 | Lorundrostat 12.5 mg BID - Part 1 | Lorundrostat 25 mg BID - Part 1 | Lorundrostat 12.5 mg QD - Part 1 | Lorundrostat 50 mg QD - Part 1 | Lorundrostat 100 mg QD - Part 1 | Placebo - Part 2 | Lorundrostat 100 mg QD - Part 2 | Run-in |
|---|---|---|---|---|---|---|---|---|---|
| Coronary artery diseaseCardiac disorders | 0/30 | 0/22 | 0/30 | 1/23 | 0/28 | 0/30 | 0/6 | 0/31 | 0/305 |
| Metastases to peritoneumNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/30 | 0/22 | 0/30 | 1/23 | 0/28 | 0/30 | 0/6 | 0/31 | 0/305 |
| HyponatremiaMetabolism and nutrition disorders | 0/30 | 0/22 | 0/30 | 0/23 | 0/28 | 0/30 | 0/6 | 1/31 | 0/305 |
| Event | Placebo - Part 1 | Lorundrostat 12.5 mg BID - Part 1 | Lorundrostat 25 mg BID - Part 1 | Lorundrostat 12.5 mg QD - Part 1 | Lorundrostat 50 mg QD - Part 1 | Lorundrostat 100 mg QD - Part 1 | Placebo - Part 2 | Lorundrostat 100 mg QD - Part 2 | Run-in |
|---|---|---|---|---|---|---|---|---|---|
| HyperkalemiaMetabolism and nutrition disorders | 1/30 | 5/22 | 9/30 | 6/23 | 3/28 | 8/30 | 0/6 | 8/31 | 3/305 |
| Blood sodium decreasedInvestigations | 0/30 | 0/22 | 0/30 | 0/23 | 0/28 | 0/30 | 1/6 | 0/31 | 0/305 |
| Glomerular filtration rate decreasedInvestigations | 1/30 | 3/22 | 0/30 | 1/23 | 0/28 | 5/30 | 0/6 | 1/31 | 0/305 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/30 | 1/22 | 0/30 | 0/23 | 0/28 | 0/30 | 1/6 | 0/31 | 0/305 |
| Urinary Tract InfectionInfections and infestations | 0/30 | 0/22 | 3/30 | 1/23 | 2/28 | 1/30 | 0/6 | 2/31 | 0/305 |
| Blood creatinine increasedInvestigations | 0/30 | 0/22 | 0/30 | 0/23 | 0/28 | 3/30 | 0/6 | 1/31 | 0/305 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/30 | 0/22 | 0/30 | 0/23 | 0/28 | 1/30 | 0/6 | 3/31 | 0/305 |
| Cortisol decreasedInvestigations | 1/30 | 2/22 | 1/30 | 0/23 | 0/28 | 0/30 | 0/6 | 0/31 | 0/305 |
| HypertensionVascular disorders | 0/30 | 0/22 | 1/30 | 2/23 | 2/28 | 0/30 | 0/6 | 0/31 | 1/305 |
| Orthostatic hypotensionVascular disorders | 0/30 | 1/22 | 0/30 | 2/23 | 0/28 | 0/30 | 0/6 | 0/31 | 0/305 |
The Baseline Analysis Population consisted of all randomized subjects. This analysis set was used for summaries of subject study disposition, with subjects analyzed according to the randomized study treatment group they were assigned to.
| Age, Continuous(years) | Placebo - Part 1 | Lorundrostat 12.5 mg BID - Part 1 | Lorundrostat 25 mg BID - Part 1 | Lorundrostat 12.5 mg QD - Part 1 | Lorundrostat 50 mg QD - Part 1 | Lorundrostat 100 mg QD - Part 1 | Placebo - Part 2 | Lorundrostat 100 mg QD - Part 2 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 62.6 ± 10.7 | 68.1 ± 10.1 | 64.8 ± 9.7 | 65.2 ± 11.3 | 64.7 ± 9.5 | 68.7 ± 8.9 | 62.7 ± 12.3 | 66.6 ± 10.6 | 65.7 ± 10.2 |
| Age, Customized(Participants) | Placebo - Part 1 | Lorundrostat 12.5 mg BID - Part 1 | Lorundrostat 25 mg BID - Part 1 | Lorundrostat 12.5 mg QD - Part 1 | Lorundrostat 50 mg QD - Part 1 | Lorundrostat 100 mg QD - Part 1 | Placebo - Part 2 | Lorundrostat 100 mg QD - Part 2 | Total |
|---|---|---|---|---|---|---|---|---|---|
| <65 | 17 | 6 | 14 | 10 | 15 | 9 | 4 | 8 | 83 |
| 65-79 | 12 | 13 | 15 | 10 | 13 | 17 | 2 | 22 | 104 |
| >=80 | 1 | 3 | 1 | 3 | 0 | 4 | 0 | 1 | 13 |
| Sex: Female, Male(Participants) | Placebo - Part 1 | Lorundrostat 12.5 mg BID - Part 1 | Lorundrostat 25 mg BID - Part 1 | Lorundrostat 12.5 mg QD - Part 1 | Lorundrostat 50 mg QD - Part 1 | Lorundrostat 100 mg QD - Part 1 | Placebo - Part 2 | Lorundrostat 100 mg QD - Part 2 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 17 | 14 | 19 | 12 | 15 | 18 | 4 | 21 | 120 |
| Male | 13 | 8 | 11 | 11 | 13 | 12 | 2 | 10 | 80 |
| Ethnicity (NIH/OMB)(Participants) | Placebo - Part 1 | Lorundrostat 12.5 mg BID - Part 1 | Lorundrostat 25 mg BID - Part 1 | Lorundrostat 12.5 mg QD - Part 1 | Lorundrostat 50 mg QD - Part 1 | Lorundrostat 100 mg QD - Part 1 | Placebo - Part 2 | Lorundrostat 100 mg QD - Part 2 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 12 | 7 | 17 | 10 | 14 | 16 | 2 | 17 | 95 |
| Not Hispanic or Latino | 18 | 15 | 13 | 12 | 14 | 13 | 4 | 12 | 101 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 2 | 4 |
| Race (NIH/OMB)(Participants) | Placebo - Part 1 | Lorundrostat 12.5 mg BID - Part 1 | Lorundrostat 25 mg BID - Part 1 | Lorundrostat 12.5 mg QD - Part 1 | Lorundrostat 50 mg QD - Part 1 | Lorundrostat 100 mg QD - Part 1 | Placebo - Part 2 | Lorundrostat 100 mg QD - Part 2 | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 16 | 7 | 7 | 11 | 8 | 15 | 2 | 6 | 72 |
| White | 13 | 15 | 23 | 11 | 19 | 14 | 4 | 25 | 124 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Region of Enrollment(participants) | Placebo - Part 1 | Lorundrostat 12.5 mg BID - Part 1 | Lorundrostat 25 mg BID - Part 1 | Lorundrostat 12.5 mg QD - Part 1 | Lorundrostat 50 mg QD - Part 1 | Lorundrostat 100 mg QD - Part 1 | Placebo - Part 2 | Lorundrostat 100 mg QD - Part 2 | Total |
|---|---|---|---|---|---|---|---|---|---|
| United States | 30 | 22 | 30 | 23 | 28 | 30 | 6 | 31 | 200 |
| Body Mass Index(kg/m^2) | Placebo - Part 1 | Lorundrostat 12.5 mg BID - Part 1 | Lorundrostat 25 mg BID - Part 1 | Lorundrostat 12.5 mg QD - Part 1 | Lorundrostat 50 mg QD - Part 1 | Lorundrostat 100 mg QD - Part 1 | Placebo - Part 2 | Lorundrostat 100 mg QD - Part 2 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 31.9 ± 4.9 | 32 ± 5.2 | 30.6 ± 5.5 | 30.6 ± 4.9 | 32.0 ± 5.0 | 30.4 ± 5.5 | 32.0 ± 3.9 | 30.5 ± 4.4 | 31.1 ± 5.0 |
| Seated Automated Office-measured Systolic Blood Pressure(mmHg) | Placebo - Part 1 | Lorundrostat 12.5 mg BID - Part 1 | Lorundrostat 25 mg BID - Part 1 | Lorundrostat 12.5 mg QD - Part 1 | Lorundrostat 50 mg QD - Part 1 | Lorundrostat 100 mg QD - Part 1 | Placebo - Part 2 | Lorundrostat 100 mg QD - Part 2 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 142.9 ± 10.7 | 142.6 ± 13.3 | 142.8 ± 13.1 | 142.9 ± 13.7 | 140.0 ± 12.1 | 142.2 ± 13.4 | 135.3 ± 5.5 | 139.8 ± 9.1 | 141.6 ± 12.0 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2021 to primary completion in Sep 2022, 14 months.
Results were first posted in Jan 2024, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lorundrostat hydrobromide
Hypertension, Renal
Mineralys Therapeutics Inc.